The findings reinforce the potential of BRIUMVI in improving patient outcomes for those seeking an alternative to their previous anti-CD20 therapy. Furthermore, the article in CNS DRUGS offers an ...
A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with ...
Researchers had known that there was something odd about the development of MS, and attributed it to the so-called hygiene ...
An American neurologist and an Italian epidemiologist whose work revolutionized the treatment of multiple sclerosis on ...
Previous research has shown that vitamin D deficiency can increase the risk of multiple sclerosis (MS) — and a new study ...
Alberto Ascherio and Stephen Hauser were recognized for their work uncovering the role of B cells and Epstein Barr virus in ...
Dr. Stephen Hauser knows that science doesn't always march in a straight line, but the UCSF neurologist's scientific journey ...
Live Science on MSN1d
$3 million Breakthrough Prize goes to scientists that completely changed our understanding of multiple sclerosisDr. Alberto Ascherio of Harvard and Dr. Stephen Hauser of the University of California, San Francisco (UCSF) — will share $3 ...
Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients ...
Fibrobiologics' cell therapy CYMS101 significantly increased myelin production and promoted myelin repair in a mouse model of ...
Trinity researcher’s findings highlight potential causal link between MS and Epstein Barr virus, opening up the possibility ...
Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback